{"componentChunkName":"component---src-templates-chapter-level-1-chapter-level-1-tsx","path":"/topics/giant-cell-arteritis/prescribing-information/","result":{"pageContext":{"chapter":{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","slug":"prescribing-information","fullItemName":"Prescribing information","depth":1,"htmlHeader":"<!-- begin field 504d5293-069a-483c-ab28-73b7feb7e70a --><h1>Prescribing information</h1><!-- end field 504d5293-069a-483c-ab28-73b7feb7e70a -->","summary":null,"htmlStringContent":"<!-- begin item 5506332b-1857-43c8-abe6-6e54182b5824 --><!-- begin field 87b8405f-99a7-43d7-a958-1da64aa1b1a6 --><p>Important aspects of prescribing information relevant to primary healthcare are covered in this section specifically for the drugs recommended in this CKS topic. For further information on contraindications, cautions, drug interactions, and adverse effects, see the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"e725cb98-d32f-4705-a906-a98c013e152e\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"d3cdb063-f7be-4aee-871a-a98c013e15aa\">British National Formulary</a> (BNF).</p><!-- end field 87b8405f-99a7-43d7-a958-1da64aa1b1a6 --><!-- end item 5506332b-1857-43c8-abe6-6e54182b5824 -->","topic":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90","topicId":"922f2e2a-90b2-4d8e-8df9-97f686e2dd9c","topicName":"Giant cell arteritis","slug":"giant-cell-arteritis","lastRevised":"Last revised in September 2020","chapters":[{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ffc44fb-e6ab-5564-afaf-41f6ec23ae59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes"},{"id":"b6663d8f-4d43-5493-b6ea-21be0eeae0f0","slug":"update","fullItemName":"Update"}]},{"id":"fbf9fbe8-db19-571e-9da9-58c8a33c3a25","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4a198ad6-17e2-5c80-a074-90f34f9ef1b7","slug":"goals","fullItemName":"Goals"},{"id":"a77ffdda-deba-58f0-9fec-65219eeb836f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0979f67-3177-527b-add9-89f384b45f07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c79d9855-b433-5fba-b27d-0999158ea93d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"941fce5c-cd66-5a8b-94ed-bcdf176a7c54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e4b575e0-3a70-5c29-afb2-b56f7ba46307","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ea4258e9-d463-5d81-ac84-d12cda80042f","slug":"definition","fullItemName":"Definition"},{"id":"cfe98d94-f2b6-58e5-828a-449fb49d3b2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications"},{"id":"0c5a3725-06fd-5f2f-8aae-4f12da09ec7d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis"},{"id":"e8c3752d-f9fb-5624-a000-60653edb83ac","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","fullItemName":"Management","slug":"management","subChapters":[{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"}]},{"id":"5a8fb527-3c07-5253-86eb-d10fc0d5b656","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ff1b1a4d-96ab-5f26-82ea-b4b059ac602f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"627bf4b4-8b65-59ac-8e48-1f7ac20afa3c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"403ae553-2865-56af-9e95-a012c674b4de","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17c8d522-4e76-5f45-aa32-83ed694272f1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bb85fa5d-a667-5361-b411-a3837f26bdc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1f292226-0f24-56c9-983b-c8fa1738c13f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e1a018ae-4d22-516e-8a99-d688c0d3dda6","fullItemName":"References","slug":"references","subChapters":[]}]},"subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone","summary":""}]}}},"staticQueryHashes":["3666801979"]}